(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Holocaust survivor, descendants urge High Court to allow Gaza children medical access - 2The most effective method to Distinguish the Best Material Organization in Your Space
- 37 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t
- 4Russian military plane crashes in annexed Crimea, killing 29 people on board
- 5One-third of asylum applications by Iranians approved in Germany
- ABC News' Sam Champion opens up about recent health scare
- France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown
- Cathay Pacific raises fuel surcharge on all flights by 34%
- Governments take targeted action as fuel prices hit retail
- EU waters down plans to end new petrol and diesel car sales by 2035
- Investigating the World's Chief Authentic Urban communities to Visit
- Southern Californians, your health insurance costs could rise in 2026
- Bahrain cracks down on dissent as war grinds on
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
